ERAP1

Endoplasmic reticulum aminopeptidase 1 · Q9NZ08 · ERAP1 on Sugi Atlas →

33,394 patent compounds predicted against ERAP1, 20,527 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL645270	0.59	10/20
SCHEMBL296717	0.42	7/20
Rebamipide (SCHEMBL296716)	0.48	6/20
SCHEMBL253285	0.41	6/20
Esculetin (SCHEMBL165749)	0.67	5/20
SCHEMBL485565	0.50	5/20
SCHEMBL485587	0.41	5/20
Esculin (SCHEMBL2893)	0.98	4/20
Esculin (SCHEMBL2894)	0.98	4/20
Umbelliferone (SCHEMBL542514)	0.72	4/20
SCHEMBL109411	0.57	4/20
SCHEMBL85021	0.57	4/20
Homophenylalanine (SCHEMBL44311)	0.56	4/20
Homophenylalanine (SCHEMBL44312)	0.56	4/20
Homophenylalanine (SCHEMBL130567)	0.56	4/20
SCHEMBL243575	0.52	4/20
SCHEMBL8761	0.50	4/20
SCHEMBL485736	0.50	4/20
SCHEMBL485602	0.45	4/20
Rebamipide (SCHEMBL297016)	0.44	4/20

Clinical trials — most relevant to ERAP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes	PHASE3	COMPLETED
Phenylbutyrate in Proteinuric Nephropathies	PHASE2/PHASE3	COMPLETED
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin	PHASE2/PHASE3	UNKNOWN
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	PHASE2	RECRUITING
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Factors Involved in Asthma and Airway Inflammation	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease	nan	UNKNOWN
Predicting Pancreatic Necrosis Using mitDNA	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)	nan	COMPLETED
ERA Test in Patients With Recurrent Implantation Failure	nan	UNKNOWN
LRP1 and Colon Cancer	nan	UNKNOWN
Ovarian Reserve and Matrix Metalloproteinases	nan	COMPLETED
Human Epididymis Protein 4 in Endometrial Carcinoma	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC	nan	COMPLETED
Proteomics of Primary Hyperoxaluria Type 1	nan	COMPLETED
Autophagy Bladder Cancer	nan	UNKNOWN
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
Fatty Acids Lipidome and Oxidative Stress in Liver Transplantation	nan	UNKNOWN
Genetic Variants and Regulation of Specialized Pro-resolving Mediator	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ERAP1 binder may also engage these)

Protein	Name	Similarity
Q5RFP3	—	1.000	Q5RFP3 →
A6QPT7	—	1.000	A6QPT7 →
ERAP2	Endoplasmic reticulum aminopeptidase 2	1.000	landscape →
Q9JJ22	—	1.000	Q9JJ22 →
Q9EQH2	—	0.998	Q9EQH2 →
ENPEP	Glutamyl aminopeptidase	0.997	landscape →
Q8C129	—	0.996	Q8C129 →
P97449	—	0.996	P97449 →
P15684	—	0.996	P15684 →
P79171	—	0.995	P79171 →
P50123	—	0.995	P50123 →
P16406	—	0.995	P16406 →
LNPEP	Leucyl-cystinyl aminopeptidase	0.994	landscape →
P15145	—	0.994	P15145 →
A5HUI5	—	0.994	A5HUI5 →
P97629	—	0.993	P97629 →
Q6K4E7	—	0.993	Q6K4E7 →
Q6Z6L4	—	0.993	Q6Z6L4 →
Q0J5V5	—	0.992	Q0J5V5 →
P79098	—	0.992	P79098 →
NPEPPS	Puromycin-sensitive aminopeptidase	0.992	landscape →
ANPEP	Aminopeptidase N	0.992	landscape →
D3UW23	—	0.992	D3UW23 →
P15541	—	0.992	P15541 →
A0A6J2ATK2	—	0.991	A0A6J2ATK2 →
P32454	—	0.990	P32454 →
Q0J2B5	—	0.989	Q0J2B5 →
Q32LQ0	—	0.989	Q32LQ0 →
P79143	—	0.989	P79143 →
Q95334	—	0.989	Q95334 →